新型抗抑郁药维拉唑酮的药理与临床评价

Pharmacology and clinical evaluation of the new antidepressant drug vilazodone

维拉唑酮为一种双重作用机制的新型抗抑郁药,即选择性5羟-色胺(5-HT)再摄取抑制剂和5-HT1A受体部分激动剂,2011年1月21日获得美国食品药品管理局(FDA)批准,用于成人重症抑郁症(major depressive d isorder,MDD)的治疗。其常见不良反应包括腹泻、恶心、呕吐和失眠。文中对维拉唑酮的药理作用、药动学、临床评价、安全性以及药物相互作用等进行了综述。

Vilazodone, a new type of antidepressant, possesses dual mechanism of action. It was approved for the treatment of major depressive disorder by FDA in January 21, 2011. It is a selective serotonin （5-HT） reuptake inhibitor and a partial 5-HT1A receptor agonist. The most common adverse reactions of vilazodone are diarrhea, nausea, vomiting and insomnia. The pharmacology, pharmacokineties, clinical evaluation, safety and drug interactions of vilazodone were reviewed in this paper.